labcorp

Auto Added by WPeMatico

Mission Bio raises $70 million to help scale its tech for improving the development of targeted cancer therapies

California-based startup Mission Bio has raised a new $70 million Series C funding round, led by Novo Growth and including participation from Soleus Capital and existing investors Mayfield, Cota and Agilent. Mission Bio will use the funding to scale its Tapestri Platform, which uses the company’s work in single-cell multi-omics technology to help optimize clinical trials for targeted, precision cancer therapies.

Mission Bio’s single-cell multi-omics platform is unique in the therapeutic industry. What it allows is the ability to zero in on a single cell, observing both genotype (fully genetic) and phenotype (observable traits influenced by genetics and other factors) impact resulting from use of various therapies during clinical trials. Mission’s Tapestri can detect both DNA and protein changes within the same single cell, which is key in determining effectiveness of targeted therapies because it can help rule out the effect of other factors not under control when analyzing in bulk (i.e. across groups of cells).

Founded in 2012 as a spin-out of research work conducted at UCSF, Mission Bio has raised a total of $120 million to date. The company’s tech has been used by a number of large pharmaceutical and therapeutic companies, including Agios, LabCorp and Onconova Therapeutics, as well as at cancer research centers including UCSF, Stanford and the Memorial Sloan Kettering Cancer Center.

In addition to helping with the optimization of clinical trials for treatments of blood cancers and tumors, Mission’s tech can be used to validate genome editing — a large potential market that could see a lot of growth over the next few years with the rise of CRISPR-based therapeutic applications.

Powered by WPeMatico

Decrypted: Chegg’s third time unlucky, Okta’s new CSO, Rapid7 beefs up cloud security

Ransomware is getting sneakier and smarter.

The latest example comes from ExecuPharm, a little-known but major outsourced pharmaceutical company that confirmed it was hit by a new type of ransomware last month. The incursion not only encrypted the company’s network and files, hackers also exfiltrated vast amounts of data from the network. The company was handed a two-for-one threat: pay the ransom and get your files back or don’t pay and the hackers will post the files to the internet.

This new tactic is shifting how organizations think of ransomware attacks: it’s no longer just a data-recovery mission; it’s also now a data breach. Now companies are torn between taking the FBI’s advice of not paying the ransom or the fear their intellectual property (or other sensitive internal files) are published online.

Because millions are now working from home, the surface area for attackers to get in is far greater than it was, making the threat of ransomware higher than ever before.

That’s just one of the stories from the week. Here’s what else you need to know.


THE BIG PICTURE

Chegg hacked for the third time in three years

Education giant Chegg confirmed its third data breach in as many years. The latest break-in affected past and present staff after a hacker made off with 700 names and Social Security numbers. It’s a drop in the ocean when compared to the 40 million records stolen in 2018 and an undisclosed number of passwords taken in a breach at Thinkful, which Chegg had just acquired in 2019.

Those 700 names account for about half of its 1,400 full-time employees, per a filing with the Securities and Exchange Commission. But Chegg’s refusal to disclose further details about the breach — beyond a state-mandated notice to the California attorney general’s office — makes it tough to know exactly went wrong this time.

Powered by WPeMatico

Where top VCs are investing in digital health

The world of healthcare has notoriously been described as “broken” — plagued with high-friction workflows, sky-high costs and convoluted business models.

Over the past several years, a long list of innovative startups and salivating venture investors have pinned their focus on repairing the healthcare industry, but its digital transformation still appears to be in the very early innings. After a record-setting 2018, however, digital health investing continued to reach meteoric heights in 2019.

Mammoth pools of capital have flooded into various sub-verticals and business models, backing collections of new B2B and B2C companies focused on optimizing healthcare workflows, improving healthcare access and offering lower-cost distribution models. Over the past two years, digital health startups have raised well over $10 billion in funding across nearly 1,000 deals, according to data from Pitchbook and Crunchbase.

As we close out another strong year for innovation and venture investing in the sector, we asked nine leading VCs who work at firms spanning early to growth stages to share what’s exciting them most and where they see opportunity in the sector:

Participants discuss trends in digital therapeutics, telehealth, mental health and the latest in biotech and medical devices, while also diving into startups improving medical practitioner efficiency, evaluating the evolving regulatory environment and debating valuations and offering a ‘temp check’ on the market for digital health startups leveraging ML.

Annie Case, Kleiner Perkins

Although Kleiner Perkins has a long history of investing in iconic health companies, we believe it is still the early innings of digital health as a category today.

When I evaluate new opportunities in the space, I often start by thinking through how the company will move the needle on cost, quality, and access to care — the “iron triangle” of health care systems. Conventional wisdom has been that it’s impossible to improve all three dimensions simultaneously, but we are seeing companies leverage technology to shift this paradigm in meaningful ways.

It’s no longer just a promise. For example, Viz.ai is using artificial intelligence to detect and alert stroke teams to suspected large vessel occlusion strokes, enabling patients to get treatment faster. Their workflows improve access to life-saving care, deliver higher quality through reduced time to treatment (every minute counts as ‘time is brain’ in stroke care), and dramatically reduce the costs associated with long-term disability.

We are also seeing companies provide this type of tech-enabled care outside of the hospital setting. Modern Health is a mental health benefits platform that employers are making available to their employees. The platform triages individual employees to the right level of care, providing clinical care to those with diagnosable depression or anxiety, and making self-guided or preventative care available to everyone else. Their solution improves quality and access by offering mental health services to every employee and reduces the cost associated with untreated mental illness, lost productivity, or employee churn.

Heading into 2020, we’re eager to back digital health companies in new areas that leverage technology to impact cost, quality, and access. A few spaces that I’m excited about are behavioral health (mental health, substance abuse, addiction, etc), care navigation, digital therapeutics, and new models integrating telehealth, remote care and AI to better leverage medical professionals’ time.

Zavain Dar and Adam Goulburn, Lux Capital

Below are some thoughts and coming predictions on health tech broadly:

  1. Digital therapeutics continue to pick up steam — on the back of Pear and Akili, more companies push to FDA and enter the market. In addition, broader consumer platforms like Calm and Headspace look to broaden their offerings by investigating clinical approvals.
  2. At least one major pharma looks to expand its consumer surface area by acquiring one of the new digital, consumer-facing generics platform (ex Hims, Ro, NuRx).
  3. Venture funding for biotech continues to boom with at least three Series A’s of $100M or more in size.
  4. Drug discovery for neurodegeneration sees a renaissance. High-profile failings of Biogen and the beta-amyloid hypothesis sees a shift of innovation to early-stage biotech and venture creation.
  5. Big pharma has its DeepMind moment acquiring at least one machine-learning (AI) enabled drug discovery company.
  6. Clinical trial tech investments heat up; new companies and technologies emerge to make trials patients first and systems get smarter at finding the right patients at their point of care; large incumbents like IQVIA, LabCorp and PPD get acquisitive.
  7. At least three traditional Sand Hill Road tech venture firms open life science practices or raise dedicated funds.
  8. Machine learning targets chemistry driven by large advancements in transformer (NLP) models; has the time for computational chemistry finally come?
  9. HCIT sees a renaissance driven by increased CIO responsibility towards data interoperability. Companies either working on federated ML to allow systems to speak to each other or lightweight edge applications enabling rapid clinical deployment will see quick uptake and traction, until now impossible in HC.

Kristin Baker Spohn, CRV

In the last 10 years, digital health has exploded. Over $16B has been invested in the sector by VCs and we’ve seen IPOs from Livongo, Progyny and Health Catalyst, just in the last year alone. That said, there’s still a lot that mystifies people about the sector — there are spots that are overheated and models that will struggle to deliver venture scale outcomes. I’ve seen digital health evolve first hand as both an operator and investor, and I’m more excited than ever about the future of the space.

A few areas and trends that I’ve been following recently include:

Powered by WPeMatico

At-home blood testing startup Baze rakes in $6 million from Nature’s Way

By now, the venture world is wary of blood testing startups offering health data from just a few drops of blood. However, Baze, a Swiss-based personal nutrition startup providing blood tests you can do in the convenience of your own home, collects just a smidgen of your sanguine fluid through an MIT manufactured device, which, according to the company, is in accordance with FDA regulations.

The idea is to find out (via your blood sample) which vitamins you’re missing out on and are keeping you from living your best life. That seems to resonate with folks who don’t want to go into the doctor’s office and separately head to their nearest lab for testing.

Most health professionals would agree it’s important to know if you are getting the right amount of nutrition — Vitamin D deficiency is a worldwide epidemic affecting calcium absorption, hormone regulation, energy levels and muscle weakness. An estimated 74% of the U.S. population does not get the required daily levels of Vitamin D.

“There are definitely widespread deficiencies across the population,” Baze CEO and founder Philipp Schulte tells TechCrunch. “[With the blood test] we see that we can actually close those gaps for the first time ever in the supplement industry.”

While we don’t know exactly how many people have tried out Baze just yet, Schulte says the company has seen 40% month-over-month new subscriber growth.

That has garnered the attention of supplement company Nature’s Way, which has partnered with the company and just added $6 million to the coffers to help Baze ramp up marketing efforts in the U.S.

Screen Shot 2019 08 30 at 2.27.12 PMI had the opportunity to try out the test myself. It’s pretty simple to do. You just open up a little pear-shaped device, pop it on your arm and then press it to engage and get it to start collecting your blood. After it’s done, plop it in the provided medical packaging and ship it off to a Baze-contracted lab.

I will say it is certainly more convenient to just pop on a little device myself — although it might be tricky if you’re at all squeamish, as you’ll see a little bubble where the blood is being sucked from your arm. For anyone who hesitates, it might be easier to just head to a lab and have another human do this for you.

The price is also nice, compared to going to a Quest Diagnostics or LabCorp, which can vary depending on which vitamins you need to test for individually. With Baze it’s just $100 a pop, plus any additional supplements you might want to buy via monthly subscription after you get your results. The first month of supplements is free with your kit.

Baze’s website will show your results within about 12 days (though Schulte tells TechCrunch the company is working on getting your results faster). It does so with a score and then displays a range of various vitamins tested.

I was told that, overall, I was getting the nutrients I require with a score of 74 out of 100. But I’m already pretty good at taking high-quality vitamins. The only thing that really stuck out was my zinc levels, which I was told was way off the charts high after running the test through twice. Though I suspect, as I am not displaying any symptoms of zinc poisoning, this was likely the result of not wiping off my zinc-based sunscreen well enough before the test began.

For those interested in conducting their own at-home test and not afraid to prick themselves in the arm with something that looks like you might have it on hand in the kitchen, you can do so by heading over to Baze and signing up.

Powered by WPeMatico